Lung Cancers Recruiting Phase 2 Trials for Ipilimumab (DB06186)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03406715Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)Treatment
NCT03693014A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsTreatment